Blackhawk Growth’s MindBio Therapeutics Looks to Expand Microdosing Clinical Trials

Blackhawk Growth’s MindBio Therapeutics Looks to Expand Microdosing Clinical Trials

Vancouver, British Columbia – November 01, 2021 – Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that MindBio Therapeutics Pty Ltd (“MindBio”) is working to expand its microdosing clinical trials. MindBio is a multi-disciplinary company pioneering new treatments for mental health conditions using psychedelic medicines, technology assisted mental health interventions and psychedelic assisted psychotherapies.

MindBio is currently undertaking a world’s first clinical trial of its kind. In its phase 1 clinical trial microdosing LSD (Lysergic Acid Diethylamide), MindBio is microdosing LSD to 80 healthy participants who take the drug at home in the same way that they would take any other medication. MindBio will lead phase 2 clinical trials microdosing LSD to patients with major depressive disorder and in patients with late-stage cancer – with those trials set to begin in mid-2022.

Pre-clinical research has demonstrated that psychedelic substances, including LSD, psilocybin, ayahuasca and DMT, affect neuroplasticity after acute and chronic administration. The data generated from in-vitro studies conducted by the Beckley Foundation1 demonstrated neuroplasticity by the presence of Brain Derived Neurotropic Factor (BDNF) in blood plasma. Studies conducted at the University of California, Davis2 have also shown that microdosing psychedelics such as LSD and psilocybin promote increased neurite growth, spine density and synaptogenesis.

MindBio is currently assessing natural psilocybin and potential analogs as a candidate for phase 1 microdosing clinical trials. The company can scale microdosing clinical trials to other substances quickly and cost effectively. MindBio is seeking advice on designing the clinical trial protocols given the potential for psilocybin to treat a number of mental health conditions such as major depressive disorder, PTSD and anxiety.

In addition, Blackhawk’s CEO, Frederick Pels, will be contributing to the psychedelics microdosing discussions at the upcoming Wonderland convention in Miami, where MindBio is a Gold Sponsor. The event is being promoted by conference organiser Microdose as “the biggest psychedelics business event, ever”.

1.https://www.beckleyfoundation.org/2018/06/13/psychedelics-promote-neural-plasticity/

2.https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30755-1

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Red Light Holland Expands the iMicrodose Brand and Unveils New iMicrodose Products: Triniti, Uniti and Mindfuli

Red Light Holland Expands the iMicrodose Brand and Unveils New iMicrodose Products: Triniti, Uniti and Mindfuli

Toronto, Ontario–(Newsfile Corp. – October 8, 2021) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company”), an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles, is pleased to announce they have unveiled new iMicrodose Products powered by Red Light Holland. The new iMicrodose magic truffles Triniti, Uniti and Mindfuli will be made available for sale (Business to Business) through Red Light Holland’s wholly owned subsidiary SR Wholesale (“SR Wholesale”) in the Netherlands and Business to Consumer through the company’s web site www.iMicrodose.nl by November, 2021.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/2017/99024_7423771954803b17_001.jpg

 iMicrodose Packs (Triniti, Uniti, OG, Mindfuli) powered by Red Light Holland

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/2017/99024_7423771954803b17_001full.jpg

Triniti, Uniti and Mindfuli Magic Truffles join the original iMicrodose packs powered by Red Light Holland, which are currently in 25 smart shops plus available online in 3 other e-commerce sites, including www.iMicrodose.nl. Triniti, Uniti and Mindfuli will be produced and packaged in the Red Light Holland Truffle farm, in Horst, The Netherlands. The company is continuously growing three Truffle strains, Mexicana, Galindoi and Tampanensis which will be used for the new iMicrodose Product offerings.

“What’s really exciting is we believe we are the first company in the Netherlands to offer microdosing with 3 different varieties of Magic Truffles in one package, as Triniti powered by Red Light Holland will contain all three strains of Truffles – Galindoi, Mexicana and Tampanensis – grown in our farm. This gives the opportunity for consumers to try all three strains and to figure out which one may be best suited for them,” said Hans Derix, Red Light Holland’s President. “Living here in the Netherlands, and watching life open up has inspired us to not just grow Magic Truffles but as well to grow the iMicrodose brand. We are proud of the packaging and design of the new iMicrodose packs and we are elated to be able to have such a large distribution wholesale network – SR Wholesale – to really push this brand and expanded product line to our retail partners.”

“Our research shows there is increased interest in microdosing with natural Psilocybin world wide. The Netherlands is our first legal market and by increasing our product offerings and testing them with our consensual data gathering app www.iMicroapp.com and our telecounseling platform we can believe we can help regulatory bodies around the world realize the potential,” said Sarah Hashkes, Red Light Holland Chief Technology and Innovation Officer. “Each iMicrodose pack comes with a QR code making it easier for customers to sign up to the iMicro App and join our community. We aim to share this unique data in Q4 of 2021.”

“We continue to grow as a company and offering new products, which we produce, to the market is part of our strategy to increase profit margins. SR Wholesale will have a clear focus on selling the new iMicrodose packs which come directly from our farm in the Netherlands showing true vertical integration,” said Todd Shapiro, Chief Executive Officer and Director of the Company. “We have a clear plan to get Red Light Holland products into many more retail stores and we will continue to push for sales on our e-commerce online platform at www.iMicrodose.nl. We’re very proud to be providing responsible access now and we love that the iMicrodose line-up continues to expand giving end consumers the ability to try more products.”

iMicrodose packs Triniti, Uniti and Mindfuli powered by Red Light Holland will be made available at www.iMicrodose.nl and via SR Wholesale to retail shops in the Netherlands to adults 18+ by early November 2021.

About Red Light Holland

The Company is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal market within the Netherlands.

For additional information on the Company:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: todd@redlighttruffles.com
Website: https://redlighttruffles.com/

Forward-Looking Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or their respective subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Examples of such information include statements with respect to: the continuous growth of truffles in the Company’s farm in Horst, the Netherlands, the anticipated sales abilities, network, connections and the reach of SR Wholesale and the amount of retail shops products are currently in; the commencement and projected sales’ dates regarding the Company’s iMicrodose Products from SR Wholesale and/or the Company’s website www.iMicrodose.nl; statements about the future of the Company’s iMicrodose Products, the iMicro App, tele-counselling support, the collection of data, including with respect to the growth and future sales; and expectations for other economic, business, and/or competitive factors.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, expectations regarding future growth and expansion of the operations of the business; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; risks related to infectious diseases, including the impacts of the COVID-19 pandemic; legal and regulatory risks inherent in the psychedelics industry, including the global regulatory landscape and enforcement related to psychedelics; political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the psychedelics industry; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com, including the Company’s annual information form for the year ended March 31, 2020.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws

The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

Managing pain across the globe

BLACKHAWK GROWTH’S MINDBIO THERAPEUTICS BRINGS DIGITAL MENTAL HEALTH TECHNOLOGY TO PSYCHEDELICS CLINICAL TRIALS

Could microdosing + this new technology reduce pain in cancer patients?

MindBio Therapeutics is developing a technology platform to integrate with psychedelic therapy to prevent the mental health of cancer patients from deteriorating.

By utilizing wearable devices, the platform is designed to help with pain management to prevent depression, existential distress and anxiety.

MindBio Therapeutics will use the mindfulness app in an upcoming  Phase 2 microdosing trial, which is funded by the New Zealand government, to see if it provides additional benefits to late-stage cancer patients compared to microdosing alone.

The company aims to commercialize the application globally and believes the tech has potential to receive government funding in Europe.

PDF of article

Blackhawk Growth’s MindBio Therapeutics Successfully Progressed to the Second Half of their Phase 1 Microdosing Clinical Trial

Blackhawk Growth’s MindBio Therapeutics Successfully Progressed to the Second Half of their Phase 1 Microdosing Clinical Trial

Vancouver, British Columbia – TheNewswire – October  04, 2021 – Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its subsidiary, MindBio Therapeutics, has successfully progressed to the second half of their fully funded Phase 1 clinical trial microdosing LSD to patients – this is the largest and first safety study of its kind anywhere in the world. The progress in its clinical trials makes MindBio a step closer towards commercialization and bringing new therapies to market.

The clinical trials have been approved by the New Zealand Government who also contributed NZ$600,000 in funding to support this important safety study. Furthermore, the Government of New Zealand has provided an import license and approval for the substances to be administered at home. It is the first clinic trial of its kind in the world that tests microdosing of 80 participants with psychedelics in a community setting.

MindBio is developing into a multi-disciplinary psychedelics platform conducting clinical trials and drug formulation, and technology development through its agreement with Digital Mind Technology and psychedelic assisted therapies with LeichtMind clinics that is also owned by Blackhawk.

“These clinical trials are a first of their kind, anywhere in the world and are unique because of the fact that the New Zealand Government has given approval for LSD to be imported, experimented with in a laboratory and for a doctor to prescribe LSD in microdoses for patients to take at home as they would any other medication” says Frederick Pels, CEO of Blackhawk Growth Corp.  “We are very pleased that the clinical trials have completed their first half and are progressing towards the finish line within budget and timeframes. We look forward to updating our shareholders in the coming weeks.”

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Even boomers want to microdose

Red Light Oregon Market Research Shows High Interest in Psilocybin Services With 86% of Adults Interested in Microdosing

New market research shows a growing interest in psilocybin services!

Red Light Oregon, a 50/50 joint venture between Red Light Holland (TRUFF) and Halo Collective (HALO), conducted market research to help the Oregon Psilocybin Advisory Board (OPAB) and health officials make informed regulations.

Of 473 Oregonian adults surveyed, 86% showed in interest in microdosing, including 94% of Gen Z and 74% of Boomers. 84% said they were interested in the mental health effects of psilocybin, with 49% interested in paying for psilocybin services. As a result, Red Light Oregon launched an advocacy program to educate the OPAB and health officials on the benefits of microdosing.

The survey also found that 37% of adults, mainly minorities, did not know what psilocybin is, so the company is launching a community outreach program to educate underserved populations on psilocybin’s therapeutic effects.

PDF of article

Red Light Holland: Initial Results From Red Light Oregon Market Research in Oregon Show 86% of Adults Interested in Psilocybin Services are Interested in Microdosing

Red Light Holland: Initial Results From Red Light Oregon Market Research in Oregon Show 86% of Adults Interested in Psilocybin Services are Interested in Microdosing

Toronto, Ontario–(Newsfile Corp. – September 29, 2021) – Red Light Oregon, Inc. (“Red Light Oregon“) a 50/50 joint venture of Halo Collective Inc. (NEO: HALO) (OTCQB: HCANF) (FSE: A9K) (“Halo Collective“) and Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF), (“Red Light Holland“), is pleased to announce preliminary findings from a statistically significant and representative market study of Oregon adults. The market research study (the “Market Research Study“), aimed to gather insights on the likely beneficiaries of Measure 109 and the legalization of psilocybin services by the Oregon Health Authority (“Psilocybin Services“) for adults in Oregon and help support the Oregon Psilocybin Advisory Board (OPAB) and health officials in making data-informed regulations.

The market research utilized an online survey with 13 questions answered by 473 Oregonians. The survey was powered by Dynata Insights Platform to ensure accurate quota sampling. The data was analyzed by data scientist Alicia Chen.

Some Initial data from the Market Research Study has uncovered:

● 86% of adults interested in Psilocybin Services are interested in microdosing.
● 49% of those interested in Psilocybin Services are interested in services such as increasing creativity (35%), exploring their mind (29%) and exploring spirituality (29%).
● Oregonians who are not interested in Psilocybin Services because they don’t want to pay for them list their largest concern is supporting Big Pharma.
● 84% of those interested in Psilocybin Services are interested in services to help with their mental health.
● While nearly half of all adults (49%) are interested in paying for Psilocybin Services, 37% of Adults in Oregon do not know what psilocybin is. In addition, women, people who have not completed a college degree, and Asian minorities in Oregon are less likely to know what psilocybin is.
● On average, people would like to pay around $100 USD for a psilocybin therapy session and approximately $50 USD for a microdosing session. However, there is a significant difference between those in lower-income brackets vs. higher income brackets ($93 USD vs. $223 USD, respectively).
● There is a trend showing younger adults are more interested in Microdosing than Boomers (94% Gen Z, 74% Boomers), although it did not reach statistical significance in the sample size.

Based on this data, Red Light Oregon has:

● Launched a community outreach program to educate the public and health care providers about the latest scientific research around psilocybin and the opportunities of Measure 109. Red Light Oregon will be focusing on reaching out to underserved populations, as seen in the data, which have not had the privilege to be exposed to the potential benefits of psilocybin. The program will utilize Wisdom, a VR app that explains the effects of psilocybin on the brain. You can register to receive more information on: https://redlightoregon.com/.
● Launched an advocacy program to educate the Oregon Psilocybin Advisory Board and Oregon health officials around the potential benefits of microdosing and the ability to increase the equity of Measure 109 with regulation specifically addressing microdosing, which is a lower-priced service. Red Light Oregon aims to work with Oregon authorities utilizing Red Light Oregon’s legal advisor to assist in bridging the gap between regulations and what the people in Oregon want.

Below are some of the answers from the 49% of adults in the sample from Oregon interested in paying for Psilocybin Services.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/2017/97989_b4d06c49c41a68f4_001.jpg

Figure 1

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/2017/97989_b4d06c49c41a68f4_001full.jpg

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/2017/97989_b4d06c49c41a68f4_002.jpg

Figure 2

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/2017/97989_b4d06c49c41a68f4_002full.jpg

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/2017/97989_b4d06c49c41a68f4_003.jpg

Figure 3

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/2017/97989_b4d06c49c41a68f4_003full.jpg

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/2017/97989_b4d06c49c41a68f4_004.jpg

Figure 4

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/2017/97989_b4d06c49c41a68f4_004full.jpg

“The data Red Light Oregon has received, so far, from Oregon is showing the immediate need people have for psychedelic services to help with mental health. The data also shows many of them are interested in microdosing,” said Todd Shapiro, CEO, and Director of Red Light Holland. “Measure 109 is focused on equity, and equity starts with education, which is why we have launched our community outreach program. Oregonians have also shown us their genuine concern around supporting Big Pharma and Red Light Oregon is committed to being the people’s company starting by listening to what the people want while advocating for legal access through education, information, and responsible use.”

“With 51% of adults interested in Psilocybin Services and 88% of those respondents being interested in microdosing, we believe there is a huge opportunity for a company with our shared expertise to provide the people of Oregon with the best services,” added Katie Field, Co-President of Red Light Oregon and President and Executive Director at Halo Collective.

“Psilocybin has meaningful potential to help people grow and heal, and it’s everyone’s responsibility to make sure the benefits from this natural substance are available to everyone even if they don’t make six figures. We are impressed with the OPAB’s emphasis on equity and hope this data will help them come up with recommendations that will ensure this goal. For Measure 109 to be equitable, it should also take into account the wants of the younger generation and make sure that group sessions and microdosing are clearly defined in the regulation to increase accessibility to lower-priced Psilocybin Services,” said Sarah Hashkes, Co-president of Red Light Oregon and Chief Technology and Innovation Officer of Red Light Holland.

Further data from the survey continues to be analyzed. An official report is estimated to be released to the public, the OPAB and health officials in mid-October.

Measure 109 will make Psilocybin Services available to 21 years and older in Oregon who think they can benefit from them without a need for medical diagnosis. The service must include a required prep-session, psilocybin session in a licensed facility supervised by a licensed facilitator and a possibility of an integration session. On December 31, 2022, the Oregon Health Authority will prescribe forms and regulations necessary for the exact implementation.

About Red Light Oregon

Red Light Oregon is an Oregon-based company that is a 50/50 joint venture between Halo Collective Inc. and Red Light Holland Corp. Red Light Oregon is developing a commercialization strategy for Psilocybin Services in Oregon utilizing a holistic approach based on the latest neuroscience research and in accordance with Measure 109, which is a measure aimed at legalizing Psilocybin Services. In addition, Red Light Oregon focuses on increasing accessibility and equity to Psilocybin Services in Oregon by promoting education, research, and accessible pricing.

About Halo Collective Inc.

Halo Collective is a leading, vertically integrated cannabis company that cultivates, extracts, manufactures, and distributes quality cannabis flower, oils, and concentrates and has sold approximately eleven million grams of oils and concentrates since inception. The company continues to expand its business and scale efficiently, partnering with trustworthy leaders in the industry who value Halo Collective’s operational expertise in bringing top-tier products to market.

Halo Collective currently operates in the United States in Oregon and California, Canada, Southern Africa in the Kingdom of Lesotho, and the United Kingdom. The company sells cannabis products principally to dispensaries in the U.S. under its brands Hush, Mojave, and Exhale, and under license agreements with Papa’s Herb®, DNA Genetics, Terphogz, and FlowerShop*, a cannabis lifestyle and conceptual wellness brand that includes G-Eazy as a partner and key member.

As part of continued expansion and vertical integration in the U.S., Halo Collective boasts several grow operations throughout Oregon and two planned in California. In Oregon, the company has a combined 11 acres of owned and contracted outdoor and greenhouse cultivation, including East Evans Creek, a six-acre grow site in Jackson County with four licenses owned and operated by Halo Collective and two third-party licenses under contract to sell all of their product to Halo Collective; Winberry Farms, a one-acre grow site located 30 miles outside of Eugene in Lane County with a license owned and operated by Halo Collective; and William’s Wonder Farms, a three-acre grow site in Applegate Valley, under contract to sell all of its product to Halo Collective pending the closing of Halo Collective’s acquisition of its licenses and business assets. Halo Collective has recently acquired Food Concepts LLC, a master tenant of a 55,000 sq.ft. indoor cannabis cultivation, processing, and wholesaling facility in Portland, Oregon operated by the Pistil Point entities.

In California, the company is building out Ukiah Ventures, a planned 30,000 sq. ft. indoor cannabis grow and processing facility, which will include up to an additional five acres of industrial land to expand the site. Recently, Halo Collective partnered with Green Matter Holding in California to purchase a property in Lake County, developing up to 63 acres of cultivation, comprising one of the largest licensed single site grows in California. Halo Collective also plans to expand its operations in California by opening three dispensaries in North Hollywood, Hollywood, and Westwood, one of which may serve as the first FlowerShop* branded dispensary.

In Canada, Halo Collective acquired three KushBar retail cannabis stores located in Alberta as a first in its planned entry into the Canadian market, leveraging its Oregon and California brands. With the KushBar retail stores as a foundation, the company plans to expand its foothold in Canada.

Halo Collective has also acquired a range of software development assets, including CannPOS, Cannalift, and, more recently, CannaFeels. In addition, Halo Collective owns the discrete sublingual dosing technology, Accudab. The company intends to spin-off these assets and its intellectual property and patent applications into its subsidiary Halo Tek Inc. and expects to complete a distribution to shareholders on a record date to be determined by Halo Collective.

Halo Collective has recently announced its intention to reorganize its non-U.S. operations into a newly formed entity called Akanda Corp. (“Akanda“), whose mission will be to provide high-quality and ethically sourced medical cannabis products to patients worldwide. Akanda will seek to deliver on this promise while driving positive change in wellness, empowering individuals in Lesotho, and uplifting the quality of the lives of employees and the local communities where it operates, all while limiting its carbon footprint. Akanda will combine the scaled production capabilities of Bophelo Bioscience & Wellness Pty. Ltd., Halo Collective’s Lesotho-based cultivation and processing campus located in the world’s first Special Economic Zone (SEZ) containing a cannabis cultivation operation, with distribution and route-to-market efficiency of Canmart Ltd., Halo Collective’s UK-based fully approved pharmaceutical importer, and distributor that supplies pharmacies and clinics within the U.K. With a potential maximum licensed canopy area of 200 hectares (495 acres), Bophelo has scalability that is arguably unmatched in the world today.

For further information regarding Halo Collective, see Halo Collective’s disclosure documents on SEDAR at www.sedar.com.

Connect with Halo Collective: Email Website LinkedIn Twitter Instagram

About Red Light Holland Corp.

The company is an Ontario-based corporation positioning itself to engage in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal, recreational market within the Netherlands, in accordance with the highest standards, in compliance with all applicable laws.

For additional information:

Todd Shapiro
Chief Executive Officer, Chairman, and Director
Tel: 647-204-7129
Email: todd@redlighttruffles.com
Website: https://redlighttruffles.com/

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements.

Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: statements regarding Red Light Oregon’s community outreach and advocacy programs; the intended outcomes and effects of Measure 109; statements regarding the implementation of Measure 109 by the Oregon Health Authority; Halo Collective’s expansion and vertical integration plans, including the buildout of Ukiah Ventures; Halo Collective’s intended spin-off of the assets, intellectual property, and patent applications of Accudab into its subsidiary Halo Tek Inc.; and Halo Collective’s plans to reorganize its non-U.S. operations into a newly formed entity called Akanda.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: Red Light Holland’s ability to continue as a going concern; the continued commercial viability and growth in popularity of psilocybin products; continued approval of Red Light Holland and Halo Collective’s activities by the relevant governmental and/or regulatory authorities; and the continued growth of Red Light Holland and Halo Collective.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of Red Light Holland to continue as a going concern; the risks associated with the psychedelics industry in general; increased competition in the recreational and medical psilocybin markets; the potential future unviability of the psychedelics industry; public opinion and perception of the psychedelics industry; incorrect assessment of the value and potential benefits of expansion plans and various transactions; risks associated with potential governmental and/or regulatory action with respect to the psychedelics industry; changes in general economic, business and political conditions, including changes in the financial and stock markets; and risks related to infectious diseases, including the impacts of the COVID-19 pandemic.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect Red Light Holland’s expectations as of the date hereof and are subject to change thereafter. Red Light Holland undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Blackhawk’s MindBio Therapeutics Utilizes Trip Pharma to Bring Microdosing Trials to North America

Blackhawk’s MindBio Therapeutics Utilizes Trip Pharma to Bring Microdosing Trials to North America

Vancouver, British Columbia – TheNewswire – September 23, 2021 – Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its subsidiary Trip Pharma, a Psychedelic Development and Wellness Company and operator of LeichtMind multidisciplinary clinics, has partnered with MindBio Therapeutics to launch MindBio’s microdosing trials in Canada.

MindBio Therapeutics, a 100% owned subsidiary of Blackhawk, has signed an agreement with Trip Pharma’s LeichtMind clinic to develop protocols necessary to launch clinical trials in Canada. LeichtMind has the appropriate infrastructure, detailed understanding of regulatory requirements, and highly qualified personnel to assist MindBio Therapeutics to fast track its activities in Canada. This is a significant agreement for Blackhawk that will bring the skills, expertise and training programs related to “assisted psychedelic therapies” to the Canadian landscape and connect Dr Krista Leicht to the MindBio management team.

MindBio Therapeutics is a clinical stage drug development company conducting research into microdosing and medicinal use of psychedelic medicine. It is one of a small group of companies in the world conducting advanced clinical trials in psychedelic medicine. It recently announced it will facilitate research and drug development “as a service” to the pharmaceutical industry to potential clients in the United States and Canada that will help accelerate the development of any substance or compound in the psychedelic sector. LeichtMind becomes another pillar for MindBio to build a global platform for delivering innovative and effective mental health treatments.

“The partnership between MindBio, Trip Pharma and LeichtMind provides the first of many opportunities generating new sources of revenue opportunities and establishing a global footprint of solutions for a range of medical health conditions. We look forward to updating our shareholders with our progress over the coming weeks and months ahead” said Frederick Pels, CEO of Blackhawk Growth.

Dr. Krista Leicht

Dr. Leicht is a Canadian-trained and Alberta-licensed medical doctor and psychiatrist, who brings over 20 years of clinical experience to the team. She has divided her time in a busy practice between inpatient and outpatient care, treating both the general adult psychiatry population and specializing in addressing the complex needs of developmentally handicapped individuals. Dr. Leicht maintains a hospital practice at Alberta Hospital Edmonton and sees outpatients in a South Edmonton clinic. She continues to teach medical students, residents and provides further education to family-practice colleagues. Dr. Leicht’s goal in clinical practice and in her own life has always been to go beyond — to provide unique and innovative treatments that better enrich the lives of patients is her mission.

MindBio Therapeutics Management Team:

Dr. Zena Burgess, PhD. FAICD,FAPS – Non-Executive Director

Zena serves as the Chief Executive Officer of the Australian Psychologists Society and formerly as Chief Executive of the Royal Australian College of General Practitioners. She is a member of the international advisory board of Connext2MyDoctor and the telehealth influencers alliance. She is also a director of the Australian Patients Association and Chair of the board subcommittee on governance and risk of the Victorian Farmers Federation. Zena has substantial experience serving on boards of government entities. She holds a PhD in psychology from the Australian Catholic University and a Master of Business Administration from Monash University and a Master of Education from La Trobe University. She has a wealth of experience in health changes and strategic advocacy to governments.

Gavin Upiter – Chairman

Gavin has over 25 years of experience leading companies in the pharmaceutical sector. Engineering qualified, prior to founding Generic Health, a leading generic pharmaceutical company which was sold to Lupin Pharmaceuticals, (NSE: LUPIN), Gavin started his executive career at Bristol Myers Squibb. He was Australian CEO of Amneal Pharmaceuticals (NYSE: AMRX) and Executive Director of Slade Health, Australia’s leading hospital pharmacy chain. Gavin founded Directo, Australia’s first online pharmaceutical B2B marketplace for pharmacies and suppliers.

Justin Hanka – Co-Founder & Director

Justin Hanka works in investment banking and financing of mergers and acquisitions and capital markets transactions. He is Non-Executive Director of EonX (CSE:EONX), a financial technology company, Non-Executive Director of Goldcar, (a Europcar Company listed on the Euronext in France), Non-Executive Director of The Digital Tribes Company, an IT digital transformation company headquartered in Sweden. He is an experienced executive having served as Chief Operating Officer for iSelect (ASX: ISU) and having sold Helpmechoose as its CEO to Mortgage Choice (ASX:MOC). Justin’s expertise spans the pharmaceutical and health sector including pharmaceuticals, pharma-technologies, fin-techs, digital transformation and technology, influencer marketing, health and wellness, entertainment and ecommerce.

Colin Keating – Director

Colin is an experienced CEO and Managing Director having led publicly listed Hogg Robinson Group Australia (LSE) and BuyMyPlace (ASX), both large private technology led organisations and has also held senior global leadership positions with the likes of American Express. With over 25 years experience in both established and scale up businesses, Colin possesses a demonstrable track record in driving growth, shaping organisational culture and delivering shareholder value. His experience is broad and varied having worked across multiple industries including Financial Services & Payments, Corporate Travel, Property Tech, Health Tech, Data Management and Wealth Management. Colin also has deep experience working in, and advising, organisations on strategic initiatives such as capital raising, M&A activities, IPO’s and exit strategies. Having worked in the United Kingdom, Hong Kong and the US, Colin’s global experience will be of enormous benefit to Mind Therapeutics as the business grows both domestically and across international markets.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Microdosing research expands worldwide!

Wake Network, Inc. Receives Certificate of Drug Registration for Microdose Formulation in Jamaica

Yesterday, Wake Network Inc received a Certificate of Drug Registration from the Jamaican Ministry of Health & Wellness for PSIL428, its microdose formulation made from natural psilocybin.

The certification allows the company to run clinical trials on anxiety and depression and makes PSIL429 available to clinics and academic institutions across the globe. Any country with a special access program can request to import the legal formulation for patient use.

In other microdosing news, MindBio Therapeutics, a subsidiary of Blackhawk Growth Corp. (BLR), is partnering with Trip Pharma’s LeichtMind clinic to launch microdosing clinical trials in Canada!

PDF of article 1

PDF of article 2

Blackhawk Growth’s MindBio Therapeutics Opens World Class Facility for the Pharmaceutical Industry

Blackhawk Growth’s MindBio Therapeutics Opens World Class Facility for the Pharmaceutical Industry

Vancouver, British Columbia – TheNewswire – September 13, 2021 – Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to provide an update on MindBio Therapeutics Pty Ltd. (“MindBio Therapeutics”), a clinical stage drug development company conducting research into microdosing and medicinal use of psychedelic medicine.

MindBio Therapeutics is excited to announce that it will open a world class facility providing research and drug development as a service to the pharmaceutical industry to potential clients in the United States and Canada. Companies in the psychedelic and pharmaceutical industry can now contract with MindBio Therapeutics for research and drug development on any psychedelic compound. Large pharmaceutical companies are increasingly looking to create synthetics compounds of psychedelics and MindBio Therapeutics has the ideal platform and access to infrastructure to help accelerate this activity.

With its exclusive agreement with the University of Auckland, MindBio has access to expansive infrastructure to bring psychedelic medicines to market. This includes research and drug development, ethical clinical expertise, clinical trial design, regulatory approvals, and formulation expertise. They have a multidisciplinary team with an interphase between medicines, psychiatry, and technology teams that can collaborate on building world class solutions for a wide range of mental health conditions. These facilities have neuroimaging technologies including EEG and MRI technology and have also opened a new clinic research centre including 30 clinical research rooms that is supported with world class pathology labs.

MindBio’s solution is cost effective, providing fast access to research and drug development infrastructure and can service clients globally. MindBio is already in discussions with several potential customers in the United States and sees a great opportunity for potentially generating ongoing revenue and licensing income from this new service offering.

About Blackhawk Growth

Blackhawk is an investment holding looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Red Light Holland Expands iMicrodose Branded Product Offerings and Launches the Sale of All-in-One Mushroom Fruiting Extracts; Capsules and Tinctures

Red Light Holland Expands iMicrodose Branded Product Offerings and Launches the Sale of All-in-One Mushroom Fruiting Extracts; Capsules and Tinctures

Toronto, Ontario–(Newsfile Corp. – September 13, 2021) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles, is pleased to announce they have expanded their iMicrodose product offerings as their iMicrodose All-In-One Mushroom Fruiting Extracts (“iMicrodose All-In-One Fruiting Extracts“) powered by Red Light Holland are now available for sale (Business to Business) through Red Light Holland’s wholly owned subsidiary SR Wholesale (“SR Wholesale”) across Europe. As well, iMicrodose All-In-One Fruiting Extracts powered by Red Light Holland, which are available in both (i) Capsules and (ii) Tinctures, are expected to be for sale (Business to Consumer) on the company’s advanced e-commerce platform at www.iMicrodose.nl by mid October 2021.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/2017/96295_85368c29f4ff8a43_001.jpg

Pictured: iMicrodose All-In-One Mushroom Fruiting Extracts Products powered by Red Light Holland

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/2017/96295_85368c29f4ff8a43_001full.jpg

“Expanding our iMicrodose product offerings powered by Red Light Holland has always been a big part of our long term strategy to increase revenues and increase our brand exposure,” said Todd Shapiro, Chief Executive Officer and Director of the Company. “SR Wholesale has established a distribution network of over 300 companies that can sell products across Europe, including working with sub-distributors which provide products to over 1,000 shops in countries like the Netherlands, Germany, Spain, Czech, Greece, UK, France, and Portugal. Having these All-In-One Mushroom Fruiting Extracts in our product line up is very exciting as they allow us to reach out to SR Wholesale’s entire network, which fits our ultimate growth strategy in both building a responsible use recreational brand while continuing to develop new Red Light Holland products that can one day be sold across the world, if and when regulations permit. And I love the eye catching labels!”

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/2017/96295_85368c29f4ff8a43_002.jpg

Pictured: iMicrodose All-In-One Fruiting Extract powered by Red Light Holland

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/2017/96295_85368c29f4ff8a43_002full.jpg

“Our Market Research has shown us that Mushroom products are in high demand and are considered by many store owners, big or small, to be a high growth sector,” said Hans Derix, Red Light Holland’s President. “Our team in the Netherlands are very proud to be so aggressive in this sector and we look forward to launching the iMicrodose All-In-One Mushroom products via SR Wholesale and soon online at www.iMicrodose.nl. The Farm in Horst, The Netherlands and SR Wholesale continue to run very smoothly which have allowed us to focus on increasing our products for sale. We are thrilled to continue building the iMicrodose powered by Red Light Holland Brand and look forward to customer feedback.”

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/2017/96295_85368c29f4ff8a43_003.jpg

Pictured: iMicrodose All-In-One Fruiting Extract (Capsules) powered by Red Light Holland

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/2017/96295_85368c29f4ff8a43_003full.jpg

About Red Light Holland Corp.

The Company is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal market within the Netherlands.

For additional information on the Company:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: todd@redlighttruffles.com
Website: https://redlighttruffles.com/

Forward-Looking Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or their respective subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Examples of such information include statements with respect to: the anticipated sales abilities, network, connections and the reach of SR Wholesale; the commencement and projected sales’ dates regarding the Company’s All-In-One Mushroom Products from SR Wholesale and/or the Company’s website www.iMicrodose.nl; statements about the future of the Company’s iMicrodose All-In-One Mushroom Products, including with respect to the future sales; and expectations for other economic, business, and/or competitive factors.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, expectations regarding future growth and expansion of the operations of the business; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; risks related to infectious diseases, including the impacts of the COVID-19 pandemic; legal and regulatory risks inherent in the psychedelics industry, including the global regulatory landscape and enforcement related to psychedelics; political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the psychedelics industry; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com, including the Company’s annual information form for the year ended March 31, 2020.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws

The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.